New hope for ITP patients: drug combo aims to boost platelets
NCT ID NCT07234019
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with immune thrombocytopenia (ITP) whose platelet counts stayed low or came back after steroid treatment. About 160 participants will receive either the combination or rituximab alone. The main goal is to see if more people reach a safe platelet level by week 12 without needing extra rescue therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese Academy of Medical Science and Blood Disease Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug calm the immune System's attack on blood cells?
- Sleep hormone melatonin put to the test against lupus fatigue and inflammation
- Experimental injection aims to boost platelets in chronic blood disorder
- Can early jaw treatment in children prevent major surgery later?
- New combo therapy aims to boost platelets in immune disorder
- Brain training may help prevent alcohol relapse after withdrawal